Saturday, March 02, 2024

GET OUR FREE E-NEWSLETTER

“You may choose to look the other way, but you can never say again that you did not know.”

— William Wilberforce

Twelve Infants Die During Clinical Trials for FDA-Endorsed RSV Drug

On June 8, 2023, the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously (21-0) in favor of AstraZeneca and Sanofi’s new nirsevimab (Beyfortus) monoclonal antibody drug believed to provide protection for infants from respiratory syncytial virus (RSV) disease and other lower respiratory tract infections during their first year of life.1 […]

RSV Vaccine Approved by FDA for Adults 60 and Older

RSV vaccine for adults

The U.S. Food and Drug Administration (FDA) has approved a license for the world’s first respiratory syncytial virus (RSV) vaccine to be given to people 60 years of age and older. Pharmaceutical and biotechnology company GSK (formerly GlaxoSmithKline) has already begun manufacturing doses of the vaccine, which will be sold as early as this fall […]

Global Pediatric Vaccines Market to Exceed $69 Billion by 2030

vaccinating the world

A report released by Coherent Market Insights showed that pediatric vaccines market will surpass $69.482 billion by 2030.1 The main pharmaceutical companies in the global market for pediatric vaccines include Bharat Biotech, Emergent BioSolutions, GSK, Indian Immunologicals, Merck, Panacea Biotec, Pfizer, Sanofi, Serum Institute and Zydus Cadila.2 Pediatric Vaccine Approvals by Governments Will Drive Vaccine […]

Pharma Developing Bird Flu Vaccine for Humans As Animals Get Sick

vaccine for bird flu

Pharmaceutical companies GSK (formerly known as GlaxoSmithKline), Moderna and CSL Seqirus announced that they are developing and ready to test human vaccines against avian influenza H5N1 (also known as bird flu) as a precautionary measure to prepare for what they believe may be a future pandemic.1 Now that certain strains of H5N1 have infected not […]

Guillain-Barré Syndrome Linked to the RSV Vaccine

paralysis in the arm

The potential risk of Guillain-Barré syndrome (GBS) developing after receipt of Pfizer’s respiratory experimental syncytial virus (RSV) vaccine have prompted the U.S. Food and Drug Administration (FDA) to request that Pfizer conduct a post-marketing safety study if the vaccine is approved for use in the United States this spring.1 The RSV vaccine manufactured by GlaxoSmithKline […]

Search in Site

To search in site, type your keyword and hit enter